• Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.
• Collaboration combines Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s leading antibody discovery/development platforms and oncology experience.
• Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earn up to an aggregate of US$2.1 billion in development and commercial milestone payments plus low double-digit royalties.

MELBOURNE, Australia, INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies.

The collaboration combines Telix’s radiopharmaceutical development platform, global manufacturing capabilities and supply chain infrastructure with Regeneron’s extensive biologics expertise, including bispecific antibody discovery. The collaboration will include multiple solid tumor targets from Regeneron’s portfolio of antibodies, generated from VelocImmune® mice. With a shared commitment to precision oncology, the parties also plan to develop radio-diagnostics to support patient selection and treatment response assessment.

“At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities – from monoclonal and bispecific antibodies to cell therapies and beyond. Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need,” said John Lin, M.D., Ph.D., Senior Vice President of Oncology & Antibody Technology Research at Regeneron.

“Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron’s antibody technologies and oncology portfolio,” said Israel Lowy, M.D., Ph.D., Senior Vice President, Clinical Development Unit Head, Oncology at Regeneron.  “Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care.”

“The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients,” said Christian Behrenbruch, D.Phil., Managing Director and Group CEO at Telix. “We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers.”

Under the terms of the agreement, Telix will receive an upfront cash payment of US$40 million from Regeneron for access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs, with Regeneron having the option to expand to include four additional programs with additional upfront payments. Telix and Regeneron will share equally in the global commercialization costs and potential profits, with Telix retaining the option to co-promote certain potential products. Should Telix opt-out of the co-funding model for a particular program, it is instead eligible to receive up to US$535 million in development and commercial milestones, plus low double-digit royalites on future net sales, for that program.

Telix and Regeneron will also jointly develop diagnostic assets, with Telix leading commercialization and Regeneron receiving a set percentage of profits.

About Regeneron         

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, including VelociSuite® which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. 

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Contacts

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Telix Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs, including with respect to any therapeutic radiopharmaceuticals that may be co-developed under Telix’s strategic collaboration with Regeneron; the potential for the collaboration agreement with Regeneron, or any other license, collaboration, or supply agreement, to be cancelled or terminated without achieving its objectives and at material cost to Telix; potential of future disputes with collaboration partners, licensees, vendors and other third parties; the potential of combining Telix’s radiopharmaceutical development platform, global manufacturing capabilities, and supply chain infrastructure with Regeneron’s expertise in biologics; the ability of Telix’s collaborators, licensees, suppliers, or other third parties to effectively perform research, development, manufacturing, distribution, and other steps related to Telix’s obligations, products and product candidates developed under the collaboration; the ability of Telix to manage supply chains for multiple products and product candidates developed independently or under the collaboration; Telix’s and its collaborator’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s or collaboration product candidates; Telix’s general sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s and collaboration product candidates, if or when they have been approved; uncertainty of the utilization, market acceptance, and commercial success of Telix’s products and product candidates developed under the collaboration; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates including those developed under the collaboration; estimates of Telix’s expenses, future revenues, capital requirements and financial obligations, or potential payments and profit share under the collaboration; Telix’s financial performance; developments relating to Telix’s competitors and industry, including potential competition with products produced by Regeneron outside the collaboration; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s and collaboration product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

HONG KONG, April 13, 2026 /PRNewswire/ — J&T Global Express Limited (“J&T Express” or “J&T” or “the Company”, stock code: 1519.HK), a global logistics service provider, today announced its business update and operating metrics for the first quarter ended March 31, 2026. During the reporting period, the Company’s total parcel volume reached 8.326 billion, up 26.2% year-on-year (“YoY”), with average daily parcel volume reaching 92.5 million. In particular, non-China parcels accounted for 35.1%, representing an increase of 4.3 percentage points on a quarter-on-quarter basis (“QoQ”). Overall business momentum remained strong, with particularly strong performance in Southeast Asia and other markets (excluding China and Southeast Asia). Operating metrics continued to improve, reflecting the Company’s ongoing expansion and solid operational execution across global markets.

As a leading express logistics provider in Southeast Asia, J&T Express maintained its strong growth momentum in the region in the first quarter. Parcel volume in Southeast Asia rose 79.9% YoY to 2.768 billion, with average daily parcel volume reaching 30.8 million and peak daily volume exceeding 47 million. The strong growth reflected the Company’s continued gains in operating efficiency across the region, as well as deeper cooperation with major e-commerce platforms, rapidly growing market demand and peak-season business growth driven by the Ramadan shopping season. As of March 31, 2026, J&T continued to expand capacity in the region, with its line-haul vehicles in Southeast Asia increasing to 6,200 vehicles and the number of automated sorting lines rising to 73 from 64, further improving processing efficiency.

In China, J&T Express adapted to industry changes by proactively adjusting its strategy and continued to improve network efficiency and client structure through refined management. In the first quarter, parcel volume in the market reached 5.404 billion, up 8.4% YoY, with average daily parcel volume of 60 million. Growth was close to the industry average and showed a recovery from the previous quarter.

In other markets, J&T Express continued to expand its footprint and accelerate growth, with parcel volume reaching 154 million, up 100.5% YoY, and average daily parcel volume rising to 1.7 million during the first quarter. Among them, Latin America has strong consumer potential. The Company worked closely with global cross-border e-commerce platforms such as TikTok, Temu, SHEIN and AliExpress, as well as local partners including Mercado Libre, to tap the strong growth opportunities arising from the development of e-commerce and logistics. Along with business expansion, the Company added 400 outlets and 5 sorting centers in other markets in the first quarter. Meanwhile, the Company’s mature operating experience in China and Southeast Asia has continued to provide important support for the business scale-up in other markets.

Charles Hou, Group Vice President of J&T Express, said: “J&T delivered an encouraging start to 2026 in the first quarter. In Southeast Asia and other markets, we have seized growth opportunities, continued to strengthen our infrastructure and improved operating efficiency. Rapid growth in parcel volume underscores our enhanced market expansion and operating capabilities. In China, network optimization and refined management supported steady parcel volume growth. The solid operating performance in the first quarter lays a strong foundation for the Company’s full-year results.”

NEW YORK, April 12, 2026 /PRNewswire/ — ATTACK SHARK, a gaming peripheral brand specializing in affordable, high-performance mechanical keyboards, gaming mice, and accessories, has put the spotlight on its newly launched flagship X11 ULTRA carbon fiber gaming mouse, alongside details of its upcoming 2nd anniversary sale, running from April 15 to 27 on its official website.

Positioned as an upgraded version of the brand’s best-selling X11 series, the X11 ULTRA features a full-body injection-molded carbon fiber design with a proprietary forged texture, delivering a distinctive look and enhanced durability. The mouse is powered by the latest Nordic 54L15 chipset, providing improved performance.

Additional highlights include a shark fin-shaped 8K receiver with integrated indicators for real-time status tracking (polling rate, battery, and signal). Its 24K gold-plated scroll wheel and side buttons further emphasize a focus on high-end precision and craftsmanship.

As part of the anniversary campaign, the X11 ULTRA will be available at 15% off, with prices starting from $93.49, giving users early access to the brand’s latest innovation.

The anniversary promotion will take place exclusively on the official ATTACK SHARK website at https://attackshark.com/.

The event will feature sitewide savings of up to 60% across a broad product range. Popular items such as the X3 mouse, X68 keyboard, X11 mouse, R5, and R11 ULTRA will be available at discounted prices. Customers purchasing bundle combinations will receive additional discounts along with a complimentary CM02 mousepad.

The campaign will also feature four rounds of giveaway events across social platforms. On April 18, all purchases made during the day will include a special anniversary gift. Additional exclusive discount codes will be released through the brand’s Discord community, offering further savings opportunities for engaged users.

The X11 ULTRA launch underscores ATTACK SHARK’s commitment to advanced materials, high performance, and user‑centric design, while its anniversary campaign deepens global community engagement and broadens access to premium gaming peripherals.

About ATTACK SHARK

ATTACK SHARK is a global gaming peripherals brand dedicated to delivering high-performance, player-focused devices. From esports-grade mice to advanced keyboards, the brand emphasizes precision, speed, and innovation, empowering gamers of all levels worldwide.

For more information, please visit https://attackshark.com/ or connect with the brand on Social Media and Discord. To place an order, please visit ATTACK SHARK Amazon Store for the US, UK, Europe, and Japan.